Path: /organizations/denali-therapeutics
Type: Biotechnology Company
Headquarters: South San Francisco, California, USA
Founded: 2013
Stock: NASDAQ: DNLI
Market Cap: ~$2.5 billion (2025)
Key Investors: Flagship Pioneering, venBio, T. Rowe Price
Denali Therapeutics is a US biotechnology company headquartered in South San Francisco, California, focused on developing therapies for neurodegenerative diseases. Founded in 2013 as a spinout from Genentech, Denali has pioneered a unique approach to CNS drug delivery using its proprietary TransportVehicle™ (TV) platform, which enables therapeutic molecules to cross the blood-brain barrier by hijacking transferrin receptor-mediated transcytosis[1].
The company's name "Denali" references the highest mountain in North America, reflecting its ambition to tackle the highest peaks of neurological disease. Denali has positioned itself at the intersection of genetic targets (LRRK2, GBA, TREM2, SNCA) and engineered delivery platforms, forming partnerships with major pharma companies including Biogen and Takeda.
Denali's pipeline spans five therapeutic areas: lysosomal storage disorders, Parkinson's disease, Alzheimer's disease, ALS/frontotemporal dementia, and inflammatory diseases. The company uses two main delivery platforms: ETS (Engineered Transport System) for enzyme replacement therapies and OTV (Organism-Targeted Vehicle) for targeted CNS delivery of various cargo types.
| Program | Target | Indication | Phase | Notes |
|---|---|---|---|---|
| Tividenofusp alfa (ETV:IDS) | IDS enzyme | MPS II (Hunter syndrome) | Phase 2/3 | Lead lysosomal program |
| BIIB122 / DNL151 | LRRK2 | Parkinson's disease | Phase 2b | Partnered with Biogen |
| DNL126 (ETV:SGSH) | SGSH enzyme | MPS IIIA (Sanfilippo A) | Phase 1/2 | NCT06181136 |
| TAK-594 / DNL593 (PTV:PGRN) | Progranulin | FTD-GRN | Phase 1/2 | NCT05262023; partnered with Takeda |
| DNL952 (ETV:GAA) | GAA enzyme | Pompe disease | Phase 1 | |
| DNL628 (OTV:MAPT) | MAPT/tau | Alzheimer's disease | Phase 1 | |
| Eclitasertib | RIPK1 | Ulcerative colitis | Phase 2 | Peripheral RIPK1 inhibitor |
| Program | Target | Indication |
|---|---|---|
| DNL921 (ATV:Abeta) | Amyloid-beta | Alzheimer's disease |
| DNL111 (ETV:GCase) | GCase | Parkinson's / Gaucher diseases |
| DNL622 (ETV:IDUA) | IDUA enzyme | MPS I (Hurler syndrome) |
| DNL422 (OTV:SNCA) | Alpha-synuclein | Parkinson's disease |
The LRRK2 inhibitor program represents Denali's most advanced neurodegeneration pipeline asset, partnered with Biogen for global development and commercialization.
Background: LRRK2 (Leucine-Rich Repeat Kinase 2) mutations are among the most common genetic causes of Parkinson's disease, with the G2019S mutation accounting for approximately 1-2% of sporadic PD and 4-5% of familial PD[2]. LRRK2 is a large multi-domain protein with kinase activity that phosphorylates Rab GTPases (particularly Rab8a, Rab10, Rab12, Rab35), regulating lysosomal function, cilia function, and autophagy[3].
Mechanism: Pathogenic LRRK2 mutations (G2019S, R1441C/G/H, Y1699C) increase kinase activity, leading to:
BIIB122 (DNL151) is an orally bioavailable, brain-penetrant small molecule LRRK2 kinase inhibitor:
Clinical trials for BIIB122/DNL151:
Relevance to other neurodegenerative diseases: LRRK2 inhibitors are being investigated beyond PD, including for:
See LRRK2 Pathway in Parkinson's for the complete mechanistic picture.
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a microglial surface receptor critical for amyloid-beta clearance and neuroinflammatory regulation. Denali is developing TREM2-targeted programs for Alzheimer's disease[5].
Mechanism of TREM2 in Alzheimer's disease:
DNL919 (TREM2 agonist): Antibody-based TREM2 modulator for Alzheimer's disease — in preclinical/early clinical development
See TREM2 Signaling for detailed mechanisms.
Glucocerebrosidase (GCase) is a lysosomal enzyme that metabolizes glucosylceramide. GBA mutations are the most common genetic risk factor for Parkinson's disease, with heterozygous GBA mutation carriers having 5-20x increased PD risk. Denali is developing gene therapy and small molecule approaches to restore GCase activity.
DNL111 (ETV:GCase): An engineered lysosomal enzyme replacement therapy delivering functional GCase to the brain via the TransportVehicle platform[6]:
See GBA Pathway in Parkinson's for the genetic and mechanistic context.
DNL422 (OTV:SNCA): An organism-targeted vehicle carrying RNA interference or antisense oligonucleotides targeting SNCA (the alpha-synuclein gene). This approach aims to reduce alpha-synuclein protein production at the source, addressing the上游 of pathological aggregation.
Rationale:
Eclitasertib (DNL300): A peripheral RIPK1 (Receptor-Interacting Serine/Threonine Kinase 1) inhibitor developed for inflammatory diseases[7]. While primarily targeting ulcerative colitis, RIPK1 inhibition has relevance for neurodegeneration given its role in necroptosis and neuroinflammation.
Denali's proprietary TransportVehicle (TV) platform is a key differentiator enabling CNS delivery of diverse therapeutic modalities[1:1]:
Mechanism:
Platform configurations:
Applications in Neurodegeneration:
| Partner | Programs | Details |
|---|---|---|
| Biogen | BIIB122/DNL151 (LRRK2) | Global co-development and commercialization; Biogen leads late-stage development |
| Takeda | DNL593 (PTV:PGRN, FTD-GRN) | Collaboration for progranulin (GRN) program; Takeda leads TAK-594 |
| Genentech | Original founder organization | Founding science and platform development |
| Sirana | RNA-based therapies | Acquired for additional CNS delivery capabilities |
Denali's programs have broader relevance for tauopathies and atypical parkinsonism:
Progressive Supranuclear Palsy (PSP):
Corticobasal Syndrome (CBS):
Alzheimer's Disease:
Spencer et al. Transferrin receptor-mediated CNS delivery with TransportVehicle platform. Sci Transl Med. 2023. ↩︎ ↩︎
Andrei et al. LRRK2 and tau: a pathophysiological link in neurodegeneration. Nat Rev Neurol. 2023. ↩︎
Ouellette et al. LRRK2 inhibitors in Parkinson's disease: current status. Mov Disord. 2024. ↩︎
Voleti et al. BIIB122 safety and pharmacokinetics in healthy subjects. Clin Pharmacol Ther. 2023. ↩︎
Schwartz et al. TREM2 in microglia and neurodegeneration. Trends Neurosci. 2024. ↩︎
Terranova et al. DNL111: GCase gene therapy for Parkinson's and Gaucher disease. Nat Commun. 2024. ↩︎
Harris et al. Peripheral RIPK1 inhibition in inflammatory disease. J Immunol. 2023. ↩︎